STAT

APRIL 4, 2024

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes.  In

Diabetes 276

Diabetes Biosimilars 276

Express Pharma

AUGUST 8, 2024

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.

Biosimilars 86

Biosimilars Diabetes 86

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Safe Biologics

APRIL 10, 2023

This will help speed approval, increasing access to biosimilars while promoting safety and building confidence through strong post-market monitoring. The webinars will focus on unintended consequences that may result from the implementation of IRA provisions regarding biologic and biosimilar medicines. Read about the approval here.

Biosimilars 130

Biosimilars Drug Pricing Diabetes Labelling 130